Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared on X:
“Lorenzo D’Ambrosio presented data on quantitative PARP1 H-score as a predictive biomarker for trabectedin plus olaparib combination in advanced soft tissue sarcomas part of analysis of TOMAS2 study.”
You can also read:
25 Posts Not to Miss from ESMO Congress 2026: Day 3
